Industry Wire 257

March 21, 2025 Viktor Zarev 0 min read
  1. Match Day 2025 sets records as largest in history.
  2. Texas measles outbreak: It’s bad, it’s nationwide? 
  3. J&J to spend $55B building pharma plants in U.S.
  4. Medicaid work requirements could impact 5M people.
  5. 4 advances that could change tuberculosis treatment.
  6. Aledade, Humana expand VBC partnership to rural clinics.
  7. HCSC spends $3.7B on Cigna’s Medicare Advantage unit.
  8. Optum RX’s PBM payment reform boosts brand-name drugs. 
  9. Sleepiness tied to higher dementia risk in women. 
  10. Fierce Healthcare searches for ‘best company in healthcare’.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]